Search results
Results from the WOW.Com Content Network
EPOCH is an intensive chemotherapy regimen intended for treatment of aggressive non-Hodgkin's lymphoma. [1] [2] It is often combined with rituximab. In this case it is called R-EPOCH or EPOCH-R. The R-EPOCH regimen consists of: Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant;
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are cytostatic, many via ...
Pages in category "Chemotherapy regimens used in lymphoma" The following 22 pages are in this category, out of 22 total. This list may not reflect recent changes .
This page was last edited on 13 September 2014, at 17:32 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Diffuse large B-cell lymphoma (DLBCL) is a cancer of B cells, a type of lymphocyte that is responsible for producing antibodies.It is the most common form of non-Hodgkin lymphoma among adults, [1] with an annual incidence of 7–8 cases per 100,000 people per year in the US and UK.
“It’s a month away,” Rep. Mark Amodei (R-Nev.), head of the subcommittee that oversees funding for the Department of Homeland Security, told The Hill. “We’re the guys who passed s ...
Infusion of R,C,H and O components of R-CHOP. Red flask contains doxorubicin (H), the most toxic component. Prednisolone (P) is administered on the next four or five days intravenously or in tablets. [1] CHOP is the acronym for a chemotherapy regimen used in the treatment of non-Hodgkin lymphoma. CHOP consists of:
From January 2008 to December 2012, if you bought shares in companies when Christine T. Whitman joined the board, and sold them when she left, you would have a 7.0 percent return on your investment, compared to a -2.8 percent return from the S&P 500.